Xylo is a biotech startup that is using computational methods to design novel brain drugs to treat mental health disorders and neurodegeneration. Many of their drug candidates are inspired by naturally occurring psychedelic drugs but are specifically designed to not induce hallucinations. Xylo's cofounders Josh Ismin and Sam Banister join Brom Rector and Sam Tabone to discuss:

(3:25) - Xylo origins + why design novel psychedelic molecules?

10:30) - How Xylo’s AI approach is different than other non-hallucinogenic psychedelic companies like Gilgamesh and Delix

(21:30) - What is the head twitch response?

(25:30) - How Xylo’s drugs are different than other psychedelics even though they hit the same receptor (5HT2a)

(26:30) - How Lykos’ failure to get MDMA approved impacts Xylo

(32:00) - Running trials in Australia

(43:00) - How has Xylo has evolved over the years

(50:30) - How will AI change drug discovery

(53:00) - How much of the neuro receptor space has been characterized

(56:00) - Is Xylo bullish or bearish on AIMore on Xylo here: https://www.xylo.bio/

More on Brom, Sam and XEIA here: www.xeiavp.com